Trastuzumab in the Treatment of Metastatic Breast Cancer : Anticancer Therapy Versus Cardiotoxicity

Circulation - United States
doi 10.1161/01.cir.102.3.272
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Oncologist
Cancer ResearchMedicineOncology
2013English

Trastuzumab-Containing Regimens for Metastatic Breast Cancer

Cochrane Database of Systematic Reviews
2014English

Addition of Everolimus and Trastuzumab to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2019English

HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2004English

A Meta-Analysis of Incidence and Risk Factors of Trastuzumab-Induced Cardiotoxicity in Breast Cancer

Journal of Patient-Centered Research and Reviews
2015English

PTEN Expression as a Predictor for the Response to Trastuzumab-Based Therapy in Her-2 Overexpressing Metastatic Breast Cancer

PLoS ONE
Multidisciplinary
2017English

Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2016English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Changing Treatment Paradigms in Metastatic Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy